Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Updates from CAPTIVATE: ibrutinib and venetoclax for CLL

Tanya Siddiqi • 17 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Ibrutinib Venetoclax
CAPTIVATE

Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, discusses the efficacy and safety results of the use of ibrutinib and venetoclax for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Tanya Siddiqi

Expanding the CAR platform for NHL 11:30
Expanding the CAR platform for NHL
Catherine Bollard et al. • 28 Sep 2025
CAR-T in CLL: updates from the TRANSCEND-CLL-004 trial and when to choose CAR-T for these patients 2:19
CAR-T in CLL: updates from the TRANSCEND-CLL-004 trial and when to choose CAR-T for these patients
Tanya Siddiqi • 7 Feb 2025
Future directions for CAR-T therapy in CLL: the potential of combining CAR T-cells with other agents 1:29
Future directions for CAR-T therapy in CLL: the potential of combining CAR T-cells with other agents
Tanya Siddiqi • 7 Feb 2025
Why has CAR-T been more challenging to manufacture for CLL? 1:00
Why has CAR-T been more challenging to manufacture for CLL?
Tanya Siddiqi • 7 Feb 2025

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals